Study of XL999 in Patients With Previously Treated Ovarian Cancer
Public ClinicalTrials.gov record NCT00277290. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial is being conducted at multiple sites to evaluate the activity, safety, and tolerability of XL999 when given weekly to patients with ovarian cancer that has previously been treated with platinum-based chemotherapy. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.
Study identification
- NCT ID
- NCT00277290
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2006 (Type not available)
- Primary completion
- Nov 2006 (Actual)
- Completion
- Nov 2006 (Actual)
- Last update posted
- Feb 22, 2010
2006
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Cancer Care, Inc. | Greenbrae | California | 94904 | — |
| Hematology/Oncology Associates of the Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Joliet Oncology-Hematology Associates, Ltd | Joliet | Illinois | 60435 | — |
| Indiana University Cancer Center | Indianapolis | Indiana | 46202 | — |
| Harry and Jeanette Weinberg Cancer Institute at Franklin Square | Baltimore | Maryland | 21237 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Bradley Cohen | New City | New York | 10956 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00277290, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 22, 2010 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00277290 live on ClinicalTrials.gov.